about
Nucleophosmin: from structure and function to disease developmentChemotherapeutic compounds targeting the DNA double-strand break repair pathways: the good, the bad, and the promisingActivation and cleavage of SASH1 by caspase-3 mediates an apoptotic responseA data-driven structural model of hSSB1 (NABP2/OBFC2B) self-oligomerization.Cell line and patient-derived xenograft models reveal elevated CDCP1 as a target in high-grade serous ovarian cancer.Activation of membrane-bound proteins and receptor systems: a link between tissue kallikrein and the KLK-related peptidases.A structural analysis of DNA binding by hSSB1 (NABP2/OBFC2B) in solution.Elevated CDCP1 predicts poor patient outcome and mediates ovarian clear cell carcinoma by promoting tumor spheroid formation, cell migration and chemoresistance.EGF inhibits constitutive internalization and palmitoylation-dependent degradation of membrane-spanning procancer CDCP1 promoting its availability on the cell surface.hSSB1 (NABP2/OBFC2B) is regulated by oxidative stressPotent Small Agonists of Protease Activated Receptor 2.hSSB1 (NABP2/ OBFC2B) is required for the repair of 8-oxo-guanine by the hOGG1-mediated base excision repair pathway.Expression of CDCA3 Is a Prognostic Biomarker and Potential Therapeutic Target in Non-Small Cell Lung Cancer.Human single-stranded DNA binding protein 1 (hSSB1, OBFC2B), a critical component of the DNA damage response.FGFR2-activating mutations disrupt cell polarity to potentiate migration and invasion in endometrial cancer cell modelsBarrier-to-autointegration factor 1 (Banf1) regulates poly [ADP-ribose] polymerase 1 (PARP1) activity following oxidative DNA damageTargeting NF-κB-mediated inflammatory pathways in cisplatin-resistant NSCLCCDCP1 enhances Wnt signaling in colorectal cancer promoting nuclear localization of β-catenin and E-cadherin
P50
Q26739704-B21876CD-0F67-4BA2-A9B4-3F8744F823C7Q26863501-29817D5D-2B6C-4601-808A-44F4200E09EDQ30008825-51D24354-24E1-42CB-8B8A-C3858A014FCDQ36400616-3CFEA228-9473-4A67-B4BA-E5D694D17F0EQ36750564-D5611F7F-E20D-4B51-B4ED-E4A3212F6400Q38214039-B7F11AE2-6FDB-4010-A6F7-75103C0EAE03Q38291782-ADCD1F9B-4232-4997-9E65-956CCEED1BF2Q38884686-8CFEF4C9-9103-4BEB-807A-E490CC850727Q39010253-D066E643-BF56-4364-A9A4-07CD61D907AFQ42737871-98E82AB5-32E8-4C16-8565-D9B984FF14B2Q43083912-70EDE642-C994-4C3D-BDAC-370981AE52EDQ43222222-F2D7E674-2BC3-4A93-8AE6-6CA2756643AAQ51012347-E5297549-9932-4537-9641-8B426D2C5463Q51759551-09D893EC-73A0-4CFB-B1E1-04CAD244E7A5Q90007270-D21AD03F-CE2D-4755-B2F8-12C88D8AAE7FQ91656423-AE3EEF92-0623-430C-AD6C-68187C290427Q92853028-1AD8E30D-97F3-49AD-8915-321600709E48Q93023688-0556F063-5A41-4F30-87A1-4BC9F3223242
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Mark N Adams
@en
Mark N Adams
@nl
type
label
Mark N Adams
@en
Mark N Adams
@nl
prefLabel
Mark N Adams
@en
Mark N Adams
@nl
P31
P496
0000-0003-1906-5018